References
- MiravitllesM, RiberaA. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-328431503
- Food and Drug Administration. Chronic obstructive pulmonary disease: developing drugs for treatment guidance for industry (draft guidance). U.S. Department of Health and Human Services; 2016.
- EkstromM, SundhJ, LarssonK. Patient reported outcome measures in chronic obstructive pulmonary disease: which to use? Expert Rev Respir Med. 2016;10(3):351–362. doi:10.1586/17476348.2016.114659526808786
- JonesPW, QuirkFH, BaveystockCM, LittlejohnsP. A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327. doi:10.1164/ajrccm/145.6.13211595997
- JonesP, MiravitllesM, van der MolenT, KulichK. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012;7:697. doi:10.2147/COPD.S3267523093901
- AndrichD, MaraisI. A Course in Rasch Measurement Theory: Measuring in the Educational, Social and Health Sciences. Springer; 2019.
- MahlerDA, KerwinE, AyersT, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079. doi:10.1164/rccm.201505-1048OC26177074
- ZhongN, WangC, ZhouX, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015.26082625
- HashimotoS, IkeuchiH, MurataS, KitawakiT, IkedaK, BanerjiD. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study. Int J Chron Obstruct Pulmon Dis. 2016;11:2543. doi:10.2147/COPD.S11140827785010
- WedzichaJA, DecramerM, FickerJH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. doi:10.1016/S2213-2600(13)70052-324429126
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global initiative for chronic obstructive lung disease (GOLD). 2020 Available from: https://goldcopd.org/. Accessed 222, 2020.
- MeguroM, BarleyEA, SpencerS, JonesPW. Development and validation of an improved, COPD-specific version of the St. George respiratory questionnaire. Chest. 2007;132(2):456–463. doi:10.1378/chest.06-070217646240
- RaschG. Studies in mathematical psychology: I. Probabilistic models for some intelligence and attainment tests. 1960.
- AndrichD. Rasch Models for Measurement. Newbury Park, CA: Sage; 1988.
- HobartJ, CanoS. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess. 2009;13(12):iii, ix–x, 1–177. doi:10.3310/hta13120
- AndrichD. Rating scales and Rasch measurement. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):571–585. doi:10.1586/erp.11.5921958102
- WrightBD, MastersGN. Rating Scale Analysis. Mesa Press; 1982.
- AlrubaiyL, HutchingsHA, WilliamsJG. Assessing patient reported outcome measures: a practical guide for gastroenterologists. United European Gastroenterol J. 2014;2(6):463–470. doi:10.1177/2050640614558345
- AndrichD. An index of person separation in latent trait theory, the traditional KR. 20 index, and the Guttman scale response pattern. Educ Res Perspect. 1982;9(1):95–104.
- NunnallyJC, BernsteinIH. Psychometric Theory. McGraw-Hill; 1994.
- United Nations SD. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. Available from: https://web.archive.org/web/20021216043228/http://unstats.un.org/unsd/methods/m49/m49regin.htm. Accessed 812, 2020.
- LoC, LiangWM, HangLW, WuTC, ChangYJ, ChangCH. A psychometric assessment of the St. George’s respiratory questionnaire in patients with COPD using Rasch model analysis. Health Qual Life Outcomes. 2015;13:131. doi:10.1186/s12955-015-0320-726290330
- RegnaultA, HamelJF, PatrickDL. Pooling of cross-cultural PRO data in multinational clinical trials: how much can poor measurement affect statistical power? Qual Life Res. 2015;24(2):273–277. doi:10.1007/s11136-014-0765-x25190565
- CrawfordB, MonzB, HohlfeldJ, et al. Development and validation of a cough and sputum assessment questionnaire. Respir Med. 2008;102(11):1545–1555. doi:10.1016/j.rmed.2008.06.00918662868
- LeidyNK, MurrayLT. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD. 2013;10(3):393–398. doi:10.3109/15412555.2013.79542323713600
- NtritsosG, FranekJ, BelbasisL, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:1507–1514. doi:10.2147/COPD.S14639029785100
- St George’s University of London. Available from: http://www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf. Accessed September 02,2020